In the latest edition of the International Biopharma Journal, Absci and Carterra, pen an article on how high-throughput SPR technologies are helping generate some of the high quality data needed to train de novo AI drug discovery models. Read it here: https://lnkd.in/eyN_hicH #Absci #Biologics #DrugDiscovery
关于我们
Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation? platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to learn, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Our vision is to deliver breakthrough therapeutics at the click of a button, for everyone.
- 网站
-
https://www.absci.com
Absci的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Vancouver，Washington
- 类型
- 上市公司
- 创立
- 2011
- 领域
- generative AI、synthetic biology、biologics、drug discovery、antibody development、artificial intelligence、pharmaceuticals和biotechnology
地点
-
主要
获取路线
US，Washington，Vancouver，98683
Absci员工
动态
-
Cut through the hype and see real-world case studies where AI has generated novel biologics with AI. Join Absci Scientist David Spencer’s presentation, “AI-guided multiparameter antibody optimization enabled by lead-specific data” at CDD for Biologics 2024 in Boston. Learn more and register here: https://cdd-biologics.com/ #Absci #Biologics #DrugDiscovery
-
-
Absci Founder and CEO Sean McClain recently sat down with Medscape’s Sarah Amandolare to discuss the impact de novo #AI protein design could have on the drug discovery process. Check out the full article here: https://lnkd.in/g-35UMfC #Absci #Biologics #DrugDiscovery
-
In the past week, Absci joined the Morgan Stanley Global Healthcare Conference, NewYorkBIO Summit, Drug Discovery Innovation Forum, and other conferences to share exciting updates across our pipeline, platform, and partnerships. Check out the highlights below and watch some of our recent presentations here: https://lnkd.in/gXQA4qW7 Recent Highlights: ? Recent non-human primate PK data for ABS-101 demonstrated 2-3X extended half-life as compared to antibodies in clinical development ? Absci successfully fulfilled the first milestone in AI drug discovery collaboration with AstraZeneca, delivering AI de novo designed antibody sequences to AZ, advancing the sequences to AI lead optimization ? Entered into collaboration with Memorial Sloan Kettering Cancer Center (MSK), a leading cancer treatment and research center, to discover and develop novel therapeutics using generative AI for up to six programs #Absci #Biologics #DrugDiscovery
-
-
Help us use generative AI to transform the future of medicine. We’re seeking a Head of AI Structural Biology Research. Come join our mission to create better biologics for patients, faster with a state-of-the-art wet lab, cutting-edge AI models, and a team of brilliant #Unlimiters working together. Learn more here: https://lnkd.in/g3c3jN9J #Absci #Biologics #DrugDiscovery
-
-
Absci’s Founder & CEO Sean McClain recently discussed the future of personalized medicine with ZDNET’s Tiernan Ray: https://lnkd.in/gEUdcCVK #Absci #Biologics #DrugDiscovery
-
-
Absci Founder and CEO Sean McClain and CFO & CBO Zach Jonasson joined the Morgan Stanley Global Healthcare Conference today for a fireside chat covering our recent pipeline and partnership milestones. If you missed the event, you can listen to the replay here: https://lnkd.in/gZJT4-Z7 Highlights: ? Recent non-human primate PK data for ABS-101 demonstrated 2-3X extended half-life as compared to antibodies in clinical development ? Absci successfully fulfilled the first milestone in AI drug discovery collaboration with AstraZeneca, delivering AI de novo designed antibody sequences to AZ, advancing the sequences to AI lead optimization ? Entered into collaboration with Memorial Sloan Kettering Cancer Center (MSK), a leading cancer treatment and research center, to discover and develop novel therapeutics using generative AI for up to six programs #Absci #Biologics #DrugDiscovery
-
-
Curious how generative AI can be used to potentially supercharge antibody development? Download our poster on de novo design to see how we leveraged our deep learning models to design high affinity binders to an antigen that the models had never seen before. https://lnkd.in/g552jvP4 #Absci #Biologics #DrugDiscovery
-
-
Are you a CMC professional with a passion for cutting-edge science? Join us at Absci to help advance our internal pipeline of AI-generated biologics. We are gritty, creative, and pushing the limits of science in a way that no one has done before. Join us as we redefine what’s possible in pursuit of our mission to create better biologics for patients, faster. Learn more here: https://lnkd.in/gun3qTTP #Absci #Biologics #DrugDiscovery
-
-
Join Absci Head of Translational Research Amer-Denis Akkad’s presentation, “Development of an AI-designed therapeutic anti-TL1A antibody for IBD” at the Festival of Biologics Europe 2024 this October 15-17 in Basel and learn how we’re using our generative AI platform to potentially speed up the development of novel therapeutics. https://lnkd.in/gVWuntea #Absci #Biologics #DrugDiscovery
-